机构投资者提升了Gilead Science公司在高收入中的份额,提高了2025年的前景。 Institutional investors boosted Gilead Sciences shares on strong earnings and raised 2025 outlook.

机构投资者包括Wealthspire Advisors, Prudential Financial和MAI Capital Management在第二季度增加了他们对吉利德科学的股权,并引用了强的财务业绩,每股收益为2.47美元和77亿美元的收入,同比增长3%. Institutional investors including Wealthspire Advisors, Prudential Financial, and MAI Capital Management increased their stakes in Gilead Sciences during the second quarter, citing strong financial results with $2.47 EPS and $7.77 billion in revenue, up 3% year-over-year. 该公司将2025年的收入指导提高到每股8.05至8.25美元,保持2.5%的股息收益,并具有协商一致的“货币购买”评级,目标价格为130.87美元。 The company raised its 2025 earnings guidance to $8.05–$8.25 per share, maintains a 2.5% dividend yield, and has a consensus “Moderate Buy” rating with a target price of $130.87.